WELL has been an impressive growth stock for years, dating back to the pandemic when it emerged as one of the best telehealth and digital health stocks on the market.
For many investors who have followed WELL in recent years, deciding what to do as we head into 2026 can be understandably frustrating.
The company appears to be continuing to post strong numbers, expanding its clinics and improving its operations, but its stock price has been flat at best. In fact, the stock has been down for most of the year.
What makes WELL such a confusing stock right now is that the company itself appears to be performing well.
For example, in its most recent quarter, it posted record revenue and record adjusted earnings before interest, taxes, depreciation and amortization (Ebitda), and the Canadian core segment of clinics continues to see more visits, more practitioners and more demand. Management even reaffirmed its full-year revenue guidance, and the six analysts covering the stock all rate it a Buy. Yet the stock is still down about 45% from previous 2025 highs.
So it’s obviously understandable that investors are wondering whether to buy, sell, or hold WELL Health stock as we head into 2026.
Is WELL Health a reliable stock?
Before we can even assess WELL’s long-term potential, we must first ensure that the quality of the shares is high enough that we can have the confidence to buy and hold them for the long term. In the case of WELL, yes.
The first thing that should give investors confidence in owning WELL for the long term is that it operates in one of the most important and defensive sectors out there: healthcare. Healthcare is incredibly defensive, especially in Canada where it is subsidized and WELL is now focused on expanding in the future.
In addition, even as WELL has proven its ability to make value-adding acquisitions and generate reliable and consistent profits on its sales, it continues to sell non-core telehealth and digital health apps businesses in order to focus more on growing its footprint of outpatient clinics across Canada.
Not only does this help simplify operations and make revenues more predictable, but it also gives WELL a clear path to scale costs and rapidly improve profitability, especially as revenue grows.
Because WELL is not only a high-potential growth stock, but a high-quality company that you can trust to own over the long term, there is no reason to sell this outpatient facility owner/operator today. The question becomes: should you buy or hold WELL in 2026?
Why this growth stock is one of the best to buy for 2026
Whether you should buy or hold WELL Health in 2026 will depend heavily on your portfolio and how much exposure you already have. However, if you don’t already own WELL, or if you’re underexposed, it’s undoubtedly one of the best growth stocks to buy in 2026 for several reasons.
First, health technology has proven for years how quickly and efficiently it can grow. However, it doesn’t just have short-term growth potential for the coming year; WELL has the potential to further expand its activities in the coming years. So while you can buy high-quality growth stocks with a market cap of less than $1 billion, this is a substantial opportunity.
However, beyond its potential, WELL is also one of the most undervalued stocks on the TSX. It’s not just the share price that’s low. For example, right now WELL is trading at a price-to-earnings (P/E) ratio of just 12.1 times.
That’s incredibly cheap for a high-quality growth stock, and it’s even lower than its three-year average price-to-earnings ratio of 14.7 times, showing that WELL is trading as cheaply as it’s ever traded since it became profitable.
So if you’re looking for a high-quality growth stock to buy in 2026 and hold for years to come, WELL is one of the best to consider, and its average analyst price is more than 90% higher than where it’s trading today.
#Health #Stock #Buy #Sell #Hold